[1]吴昭利,唐 星,李仁廷,等.培元抗癌汤加减对晚期结肠癌脾肾亏虚证患者血浆VEGF、CA724、TGF-β1及肠黏膜屏障功能的影响[J].陕西中医,2021,(3):315-318.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.011]
　WU Zhaoli,TANG Xing,LI Renting,et al.Effect of Peiyuan Kang'ai decoction on plasma VEGF,CA724,TGF-β1 and intestinal mucosal barrier function in patients with advanced colon cancer of Pishen Kuixu syndrome[J].,2021,(3):315-318.[doi:DOI:10.3969/j.issn.1000-7369.2020.03.011]
点击复制

培元抗癌汤加减对晚期结肠癌脾肾亏虚证患者血浆VEGF、CA724、TGF-β1及肠黏膜屏障功能的影响

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年3期
页码:
315-318
栏目:
临床研究
出版日期:
2021-03-09

文章信息/Info

Title:
Effect of Peiyuan Kang'ai decoction on plasma VEGF,CA724,TGF-β1 and intestinal mucosal barrier function in patients with advanced colon cancer of Pishen Kuixu syndrome
作者:
吴昭利1; 唐 星2; 李仁廷1; 杨得振1; 司海龙1; 千维娜1
(1.陕西中医药大学附属医院,陕西 咸阳 712021; 2.西安中医脑病医院脑病一科,陕西 西安 710068)
Author(s):
WU Zhaoli; TANG Xing; LI Renting; YANG Dezhen; SI Hailong; Qian Weina
(Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang 712021,China)
关键词:
培元抗癌汤;  晚期结肠癌;  脾肾亏虚证;  肠黏膜屏障;  肿瘤转移
Keywords:
Peiyuan Kang'ai decoction;  Advanced colon cancer;  Pishen Kuixu syndrome;  Intestinal mucosal barrier;  Tumor metastasis
分类号:
R 735.3
DOI:
DOI:10.3969/j.issn.1000-7369.2020.03.011
文献标志码:
A
摘要:
目的:探讨培元抗癌汤加减在治疗晚期结肠癌脾肾亏虚证患者中的应用价值。方法:将晚期结肠癌脾肾亏虚证患者92例随机分组。对照组46例采用FOLFIRI方案,观察组46例在对照组基础上联合培元抗癌汤,治疗结束后比较疗效。结果:治疗后观察组血浆糖类抗原CA724、癌胚抗原、糖类抗原CA199低于对照组,差异有统计学意义(均P<0.05)。治疗后观察组血管内皮生长因子、转化生长因子-β1低于对照组; 治疗后观察组血浆内毒素含量、尿乳果糖/甘露醇比值低于对照组,差异有统计学意义(均P<0.05)。观察组总有效率48.94%、获益率74.47%,对照组总有效率41.30%、获益率54.35%; 观察组获益率高于对照组,差异有统计学意义(P<0.05)。观察组不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论:晚期结肠癌脾肾亏虚证患者给予FOLFIRI方案联合培元抗癌汤加减,可预防肿瘤转移,保护肠黏膜屏障,降低化疗不良反应。
Abstract:
Objective:To explore the application value of Peiyuan Kang'ai decoction in the treatment of patients with advanced colon cancer of Pishen Kuixu syndrome.Methods:92 patients with Pishen Kuixu syndrome were grouped by random number table.The control group of 46 patients received FOLFIRI chemotherapy,and the observation group of 46 patients were treated with Peiyuan Kang'ai decoction.The clinical efficacy was compared after treatment.Results:Plasma sugar antigen CA724,carcinogenic antigen,and sugar antigen CA199 in the observation group were lower(all P<0.05).The levels of vascular endothelial growth factor and transforming growth factor-β1 in the observation group were lower.The plasma endotoxin content and urine lactulose/mannitol ratio in the observation group were lower than those in the control group,differences statistically significant(all P<0.05).The total effective rate in the observation group was 48.94%,the profit rate of 74.47%; and the total effective rate of the control group was 41.30%,the benefit rate of 54.35%.The benefit rate of the observation group was higher(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,differences statistically significant(P<0.05).Conclusion:Patients with advanced colon cancer of Pishen Kuixu syndrome given FOLFIRI combined with Peiyuan Kang'ai decoction can prevent tumor metastasis,protect the intestinal mucosal barrier,and reduce adverse reactions to chemotherapy.

参考文献/References:

[1] 郜文秀,古小玲,骆菊英,等.吸烟等相关因素与大肠癌的流行病学研究[J].中国热带医学,2017,17(7):679-681.
[2] 杨小玲,何凌霄,徐 禹,等.169例结肠癌患者术后3年生存期影响因素分析[J].中国普外基础与临床杂志,2012,19(7):771-773.
[3] 徐银姝,于 杰,吴仁杰.利妥昔单抗联合FOLFIRI方案治疗晚期结肠癌的临床疗效[J].中国中西医结合消化杂志,2020,28(1):15-19.
[4] 杨 辉.健脾益气活血法联合化疗对大肠癌术后患者疗效及生存质量的影响[J].现代中西医结合杂志,2017,26(6):593-595,633.
[5] 中华人民共和国卫生和计划生育委员会医政医管局,中华医学会肿瘤学分会.结直肠癌诊疗规范[J].中华外科杂志,2015,53(12):881-894.
[6] 国家中医院要管理局.中药新药临床指导原则[M].北京:中国医药科技出版社,2002:162-167.
[7] 樊英华.香砂六君子汤配合化疗治疗结肠癌临床观察[J].陕西中医,2016,37(8):955-956.
[8] 范广明,张文彬,张 赛.老年脑肿瘤患者肿瘤切除术的临床分析[J].中国急救复苏与灾害医学杂志,2011,6(2):134-136.
[9] 杨 娟,张 琳,文小霞,等.大肠癌患者血清CEA和CA199表达与临床病理因素相关性的回顾性分析[J].中华肿瘤防治杂志,2012,19(15):1169-1172.
[10] 徐 路.4项血清肿瘤标志物水平对各期结肠癌的价值分析[J].国际检验医学杂志,2019,40(16):1985-1988.
[11] 沙晓锋,宋增芳,丁 洁,等.华蟾素胶囊联合雷替曲塞与奥利沙铂对晚期结直肠癌免疫、肿瘤标记物、基质金属蛋白酶及血管新生的影响[J].海南医学院学报,2018,24(23):2066-2069.
[12] 吴云龙,王晓辉,王 谦,等.不同年龄结肠癌患者血清内CEA、AFP、CA50、CA199和CA724的表达及意义[J].实用癌症杂志,2019,34(8):1252-1254,1274.
[13] 白 梅,任孟军.血管内皮生长因子与结肠癌的相关性研究[J].检验医学与临床,2017,14(5):719-720.
[14] Koido S,Enomoto Y,Apostolopoulos V,et al.Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines[J].Anticancer Res,2014,34(8):3917-3924.
[15] 刘 烨,高志海,安 燚.结肠癌组织中转化生长因子-β1和缺氧诱导因子-1α及血管内皮生长因子的表达及临床意义[J].中国慢性病预防与控制,2019,27(5):352-355.
[16] 姚 磊,林雨佳,高 爽,等.miR-34a通过调控TGF-β/Smad4信号通路激活自噬而降低结肠癌细胞对奥沙利铂的耐药性[J].中国普外基础与临床杂志,2018,25(6):680-688.
[17] 宋亚邛,胡海燕.VEGF、TGF-1、CA199、CA242和DKK-1联合检测对早期胰腺癌临床诊断价值研究[J].陕西医学杂志,2020,49(2):237-240.
[18] 王 燕,贡丽雅,王凤姣,等.益生菌联合肠内营养对结肠癌患者肠黏膜屏障功能及炎症反应的影响[J].中国医药导报,2019,16(14):101-103,108.
[19] 熊永强,郭云童,陈 浩,等.谷氨酰胺对结肠癌患者术后肠黏膜屏障功能的影响[J].肿瘤代谢与营养电子杂志,2018,5(1):53-58.
[20] 李德育,陈喜军,郑建萍,等.不同肠内营养对结肠癌化疗患者肠黏膜屏障保护作用的影响[J].慢性病学杂志,2016,17(10):1091-1094.
[21] 许环应,李财宝,熊旭东.大肠癌术后加用扶正解毒中药的疗效观察[J].上海中医药杂志,1996,6(2):12.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81704066); 陕西省第三届名中医传承工作室建设项目(2019003); 陕西省卫生健康委员会科研基金资助项目(2018E018)
更新日期/Last Update: 2021-03-08